Hydrogel Microparticle-Based Soft Tissue Fillers

Fully crosslinked viscoelastic hydrogel microparticles address the need for longer-lasting dermal fillers by providing durable, biocompatible, and controllable cosmetic enhancements.

JP2024545175APending Publication Date: 2024-12-05LIKARDA LLC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024534565
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-09
Filing Date
2022-12-09
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

There is a need for alternative and improved dermal fillers that provide longer-lasting aesthetic or cosmetic corrections compared to current hyaluronic acid-based fillers, which have short durations of effect.

Method used

The development of fully crosslinked viscoelastic hydrogel microparticles with defined shapes and geometries, characterized by covalent or strong ionic crosslinks, that are administered as soft tissue fillers to enhance durability and longevity of cosmetic effects.

Benefits of technology

The fully crosslinked hydrogel microparticles maintain their shape and provide prolonged cosmetic correction by adhering to the implantation site, reducing inflammatory responses, and allowing for controlled degradation when necessary, thus offering improved aesthetic outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545175000001_ABST
    Figure 2024545175000001_ABST
Patent Text Reader

Abstract

Methods, compositions, and kits for aesthetic or cosmetic soft tissue filling in a human subject. The compositions and methods are characterized as a suspension comprising a plurality of porous, viscoelastic, solid hydrogel microparticles dispersed in a carrier vehicle, each microparticle being free-standing having an exterior surface and a defined / discrete three-dimensional shape and geometry, the microparticles being substantially free of any cells, tissues, or therapeutic compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent No. 63 / 287,769, entitled Hydrogel Microparticle-Based Dermal Fillers, filed December 9, 2021, which is incorporated by reference in its entirety.

[0002] background FIELD OF THEINVENTION The present disclosure relates to fully cross-linked microparticles made from a variety of hydrogels for use as dermal or other soft tissue fillers. [Background technology]

[0003] Field Description Over the past 100 years, humans have attempted to improve their appearance, including injecting various materials into the face and other body parts to add volume and reduce wrinkles. In fact, reports of injecting autologous fat into the face date back to the 1890s. Later, paraffin was injected into women's faces in Europe. Reports of long-term complications from paraffin injections began in the early 1900s, but it was still used as a volume enhancer in parts of Asia until the 1950s. Other materials once used in the pursuit of beauty included polytetrafluoroethylene, silicone oil, and bovine collagen.

[0004] When hyaluronic acid (HA) was first approved for injection by the FDA in 2003, the field took a major leap forward. Hyaluronic acid is a polysaccharide consisting of repeating monomers (glucuronic acid and N-acetylglucosamine disaccharide units) linked in a linear chain via β-1,4 glycosidic bonds. The importance of HA as a cosmetic filler mitigated two problems with previous fillers. First, it was easy to inject. Second, it caused less frequent strong inflammatory reactions. Further beneficial features were that it could be stored at room temperature, had a long shelf life, was noncarcinogenic, and had effects lasting for several months. HA fillers are usually partially crosslinked with 1,4-butanediol diglycidyl ether (BDDE) as a crosslinker to increase durability. Summary of the Invention [Problem to be solved by the invention]

[0005] There remains a need in the art for alternative and improved dermal fillers. [Means for solving the problem]

[0006] overview This disclosure describes the first approach to use fully cross-linked viscoelastic hydrogel microparticles that can be delivered as soft tissue fillers to improve aesthetic or cosmetic features, including filling wrinkles, creating volume, correcting minor deformities secondary to aging, acne, injury or surgery, treating lack of skin elasticity, treating lack of skin tautness, and correcting soft tissue defects or voids. Thus, placement of the soft tissue filler is performed in and just above the superficial dermis, mid dermis, subcutaneous layer, and periosteum layer. In contrast to current non-cross-linked or partially cross-linked solutions or pastes, the cross-linked microparticles remain in the implanted location for a long period of time, thereby increasing the duration of the cosmetic or aesthetic correction.

[0007] Current hyaluronic acid fillers consist of partially crosslinked viscous liquid solutions with short duration of effect. Table 3 summarizes currently available HA-based fillers compared to the fully crosslinked viscoelastic hydrogel microparticles of the present invention. Comparing the crosslinking rates of the commercial products, RESTYLANE® has a low degree of crosslinking, small particle size and low durability, while JUVEDERM® Ultra has a higher degree of crosslinking and a slower degradation rate. The table shows that the molecular weight of the hydrogel microparticles of the present invention is high, as the individual crosslinked microparticles of the present invention are considered single molecules. Furthermore, the crosslinked microparticles have a significantly higher crosslinking rate. Table 4 summarizes some of the same information, but compares the characteristics of microparticles composed of polyethylene glycol (PEG) to other non-HA hydrogels marketed as human cosmetic fillers. Calcium hydroxylapatite (CaHA) is another injectable dermal filler (RADIESSE®) that contains uniform CaHA microspheres suspended in an aqueous carboxymethylcellulose gel carrier and works by stimulating collagen production at the injection site. However, this ceramic / mineral-based filler cannot be dissolved if the patient does not like the results or if there are unwanted interactions or side effects.

[0008] Described herein are methods, compositions, and kits for aesthetic or cosmetic soft tissue filling in human subjects. In one or more embodiments, a method is disclosed that includes placing or introducing a suspension comprising a plurality of porous viscoelastic solid hydrogel microparticles dispersed in a carrier vehicle to an implantation site of a subject in need thereof. Each microparticle is a free-standing body having an exterior surface and a defined / discrete three-dimensional shape and geometry, and the microparticles are substantially free of any cells, tissues, or therapeutic compounds. In one or more embodiments, the suspension is placed in the superficial dermis, mid dermis, subcutaneous layer, fascial layer, muscle layer, or periosteum layer of the subject.

[0009] Also described herein are kits for cosmetic or aesthetic soft tissue filling, comprising a plurality of porous elastic solid hydrogel microparticles, each microparticle being free-standing with an exterior surface and a defined / discrete three-dimensional shape and geometry, substantially free of any cells, tissues, or therapeutic compounds, and instructions for administration thereof.

[0010] Also described herein are various compositions for use in aesthetic or cosmetic soft tissue filling in human subjects. These compositions are generally characterized as suspensions comprising a plurality of porous, viscoelastic, solid hydrogel microparticles dispersed in a carrier vehicle, each microparticle being free-standing with an exterior surface and a defined / discrete three-dimensional shape and geometry, and the microparticles being substantially free of any cells, tissues, or therapeutic compounds.

[0011] Also contemplated herein is the use of such compositions for aesthetic or cosmetic soft tissue filling in human subjects.

[0012] The patent or application file contains at least one color drawing. Copies of this patent or patent application publication containing color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 provides images of microparticles of various defined geometric shapes that can be injected as dermal fillers: A) spherical, B) teardrop-shaped, C) elliptical, D) tubular, and E) mixed shapes. [Diagram 2] FIG. 2 provides an image showing a viscoelastic solid fragment of a hydrogel by extruding a microparticle through an opening smaller than the diameter of the microparticle. [Diagram 3] Figure 3 is an image showing the different sizes that can be produced for crosslinked particles: A) average diameter 2040+21 μm, B) average diameter 1214+46 μm, C) average diameter 361+19 μm, D) a mix of sizes. [Figure 4] FIG. 4 shows examples of different materials that can be used to make microparticles such as those shown in the figure. [Diagram 5] FIG. 5 is a schematic diagram showing one example of how a microparticle can be modified after cross-linking with a complementary molecule. [Figure 6] Figure 6 provides images showing that the hydrogels can be fluorescently labeled to track their location and duration within the body. [Figure 7] FIG. 7 provides images of hydrogel microparticles subjected to solute-controlled shrinkage. [Figure 8] Figure 8 summarizes the change in diameter of three different hydrogel chemistries when exposed to solute-controlled shrinkage. [Figure 9] Figure 9 summarizes the change in microparticle volume for three different hydrogel chemistries upon exposure to solute-controlled shrinkage. [Figure 10] FIG. 10 shows the normalized reduction in sphere volume for different concentrations of solute. [Figure 11] FIG. 11 shows the reduction in microparticle diameter (light grey) and recovery to original size (dark grey) for microparticles placed in various concentrations of solute. [Figure 12] FIG. 12 shows two methods of subcutaneous microparticle placement: as a bolus injection or a dispersion. [Figure 13] FIG. 13 provides images showing the biocompatibility of three different microparticle formulations injected near or into the omentum in healthy rats. [Figure 14] FIG. 14 shows that after 2 weeks in the rat peritoneum there is no cellular inflammation or interfibrocellular adhesion to the non-adherent microparticles. [Figure 15] FIG. 15 compares the in vivo degradation of one of the microparticle formulations to a non-biocompatible material. [Figure 16] FIG. 16 provides images of microparticles as they are enzymatically degraded over time using a particular hydrogel formulation. [Figure 17]FIG. 17 provides images of microparticles that were chemically degraded on demand. [Figure 18A] FIG. 18A shows potential degradation pathways for dissolving fully crosslinked microparticles, along with potential by-products. [Figure 18B] FIG. 18B shows potential degradation pathways for dissolving fully crosslinked microparticles, along with potential by-products. [Figure 19] FIG. 19 shows images of thiolated HA microparticles imaged after storage in water at room temperature for over four years, demonstrating no visible loss of structure in the microparticles. [Figure 20] FIG. 20 is an image of microparticles (PEG-MAL) before freezing and thawing in liquid nitrogen, showing intact microparticles after cryopreservation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Detailed Description The microparticles consist essentially of or consist of a three-dimensional matrix of fully crosslinked (via covalent bonds or strong ionic crosslinks) hydrogel polymer compounds, such that the resulting crosslinked microparticle body is characterized as a porous elastic solid (hydrogel) with reversible elastic deformation. In other words, the microparticles are semi-rigid but elastic, such that the microparticles will deflect under load and return to their original shape upon removal of the load. Hydrogel precursor compounds suitable for use in forming the microparticles include hydrogel-forming polymers, oligomers, and / or monomers, such that they can form crosslinked or network structures or matrices by covalent bonds or strong ionic crosslinks, and can hold, suspend, entrap, and / or encapsulate liquid within the interstices or pores of the resulting elastic gelling structure or matrix body (hydrogel). Preferably, the precursor compounds are functionalized hydrogel-forming polymers, oligomers, and / or monomers, meaning that the natural polymer, oligomer, or monomer backbone has been chemically modified to contain multiple chemically reactive groups (i.e., functional groups) to which covalent or ionic bonds are formed (i.e., crosslinked) during the formation of the hydrogel matrix. In this manner, the fully crosslinked hydrogel particles obtained after the sol-gel transition are characterized by not relying on molecular entanglements, van der Waals forces, or other weak molecular interactions, but instead by covalent or strong ionic bonds to form an irreversible, insoluble hydrogel having a crosslinked network or matrix throughout the material of the particle.

[0015] Microparticles are three-dimensional free-standing bodies, meaning that once their shape is formed, they retain their particular viscoelastic shape without an external support structure and are not susceptible to deformation or creep simply due to their own weight or gravity. In other words, free-standing bodies are not permanently deformable or flowable like jellies, putties, or pastes, but are elastic, and although the matrix body may yield or deform temporarily under a force, they will return to their original shape upon removal of the force unless destroyed. Microparticles typically have a particle size of less than about 2,000 μm, preferably less than about 1,500 μm, and greater than about 30 μm, preferably greater than about 100 μm or more. As used herein, "particle size" refers to the largest surface-to-surface dimension (e.g., diameter in the case of some spherical bodies). As discussed in more detail below, microparticles are preferably rounded, three-dimensional bodies with an aspect ratio of at least 0.5, preferably at least 0.7, and more preferably about 1. As used herein, "aspect ratio" refers to the ratio of the largest surface-to-surface dimension of each particle to the smallest surface-to-surface dimension (ie, particle size).

[0016] Hydrogel microparticles may also be characterized as microspheres, microbeads, or hydrogel microparticles, rather than simply "particles" or random aggregates. Depending on the polymer system used, the microparticles may generally be characterized by a Young's modulus in the range of about 1,000 Pa to about 2.5 MPa (megapascals), more preferably about 10,000 Pa to about 2 MPa, more preferably about 25,000 Pa to about 1 MPa, more preferably about 50,000 Pa to about 0.5 MPa. Although resilient and having an elastic component, upon application of sufficient force, the microparticles may crumble or break into smaller fragments, but such subsequent fragments still constitute a three-dimensional polymer matrix, albeit as smaller bodies. In other words, hydrogel microparticles are not shear thinning, and the matrix bodies themselves are not susceptible to dissolution or dilution in a solvent system, although swelling of the individual matrix bodies may occur depending on the carrier or vehicle system (i.e., when liquid moves into the interstices or pores of the matrix). In one or more embodiments, the hydrogel microparticles can be characterized as irreversible hydrogels, meaning that once fractured, the matrix crosslinks do not reform or otherwise recover or self-heal.

[0017] Exemplary polymer precursor compounds used to form the microparticles include fast gelling natural polymers that form strong matrices, such as alginate, and slow gelling polymer precursors selected from the group consisting of branched or unbranched hyaluronic acid, branched or unbranched functionalized hyaluronic acid, branched or unbranched functionalized polyethylene glycol, hyaluronan, fibrin, chitosan, collagen, polylactic acid, poly(L-lactic acid), polylactic-glycolic acid copolymer, polycaprolactone, polyvinyl alcohol, and combinations thereof.

[0018] The matrix may further comprise a crosslinker (crosslinking with the polymeric compound) selected from the group consisting of dithiothreitol, branched or unbranched functionalized polyethylene glycol, dithiol, ethylene glycol bis-mercaptoacetate, and combinations thereof. Exemplary functionalized polyethylene glycols include, but are not limited to, polyethylene glycol dithiol, polyethylene glycol diacrylate, polyethylene glycol divinyl sulfone, polyethylene glycol dimaleimide, and combinations thereof. In one or more embodiments, the polymer precursor solution is substantially free of 1,4-butanediol diglycidyl ether (BDDE).

[0019] The matrix may be homogeneous, comprising one type of covalently crosslinked polymer backbone (with or without additional crosslinkers of different polymeric types). The matrix may also be heterogeneous, comprising a mixture of two or more polymer precursors, such as a combination of high molecular weight (≧500 kDA, preferably ≧100 kDA) and low molecular weight (≦100 kDA, preferably ≦50 kDa) polymer precursors, and / or a mixture of two or more crosslinkers.

[0020] Typically, the amount of polymer precursor contained in the precursor solution is less than 50% w / w, ranging from about 1% to about 50% w / w for high molecular weight (≧500 kDa, preferably ≧100 kDa) polysubstituted polymers such as hyaluronic acid, and from about 5% to about 50% w / w for low molecular weight polymers (≦100 kDa, preferably ≦50 kDa), such as PEGDA or PEGMAL.

[0021] Examples of reactive groups from different backbone chemistries that can be used to form hydrogels with appropriate crosslinkers are shown in the table below. Some of the crosslinking reactions are initiated by UV light, while others are chemical reactions.

[0022] [Table 1]

[0023] Further exemplary precursor compounds include, but are not limited to, non-alginate polysaccharides, collagen / gelatin, chitosan, agarose, and the like. These precursor compounds may be branched polymers with multiple arms or single backbone unbranched / linear polymer chains. They can be further functionalized to attach dyes for visual observation. A particularly preferred hydrogel precursor compound is hyaluronic acid, or a hyaluronic acid / PEG mixture. The precursor compounds can also be functionalized with various chemical entities that are added to the precursor compounds during hydrogel production. These chemicals bind to the hydrogel matrix, as opposed to being encapsulated in the interstitial spaces for simple diffusion out of the microparticles.

[0024] Biocompatible hydrogels are particularly preferred. As used herein, "biocompatible" means not harmful to living tissue, more specifically, not biologically or otherwise undesirable in that it can be administered to a subject without undue toxicity, irritation, or allergic or immunogenic response, does not cause any undesirable biological effects, or does not interact in a harmful manner. Biocompatible hydrogels are selected to minimize side effects in a subject, as is well known to those skilled in the art. Additional optional components that may be included with the hydrogel precursor include fibronectin, laminin, collagen, other components of the extracellular matrix, including synthetic versions thereof.

[0025] The crosslinking profile of the microparticles can be tailored by adjusting the molecular weight of the precursor compounds, as well as the selected crosslinker, crosslinking conditions, and crosslinking process. For example, "tighter" or faster crosslinking may be desired in some embodiments to achieve a smoother bead surface and / or stronger gel by limiting the ability of molecules to leach out of the droplet / core into the surrounding environment during crosslinking. This can be achieved both by increasing the molecular weight of the precursor species (e.g., ~>40 kDa) and / or by adjusting the crosslinking chemistry or initiation method to reduce crosslinking time. Crosslinking can be accomplished by a variety of mechanisms depending on the particular hydrogel precursor compound.

[0026] In general, one technique for preparing microparticles is described in detail in U.S. Patent No. 9,642,814, filed June 3, 2015, which is incorporated herein by reference. The method includes preparing a hydrogel precursor solution consisting of a hydrogel precursor compound and a divalent cation (e.g., calcium, barium, strontium, and combinations thereof) dispersed or dissolved in a solvent system. The divalent cation is dispersed or dissolved in the solvent system along with the hydrogel precursor compound. The divalent cation should be included in the solution at a level of about 0.025 moles / liter to about 0.25 moles / liter, with the total volume of the solution being 100%.

[0027] The hydrogel precursor solution may also include any hydrogel crosslinkers, catalysts, additives, vehicles, nutrients, pH buffers, density modifiers, viscosity modifiers, etc. The hydrogel precursor solution is then combined with alginate to initiate gelation of the alginate around the hydrogel precursor solution (via an "inside-out" gelation process) to yield core / shell microparticles. Each core / shell microparticle comprises an alginate shell surrounding a liquid core comprising the hydrogel precursor solution. This generally involves dropwise addition of the precursor solution to an alginate bath, for example by generating / extruding droplets of the precursor solution that are dripped or sprayed into the alginate bath. The amount of alginate in the solution may vary, but may range from about 0.1 to about 2.0% by weight / volume, with the total volume of the solution being 100%. Generally, the viscosity of the alginate solution should be less than the viscosity of the hydrogel precursor solution. The viscosity of the alginate solution depends on the alginate concentration and the average molecular weight of the alginate polymer (i.e., the length of the alginate molecule or the number of monomer units in the chain), with longer chains resulting in higher viscosity at similar concentrations. In one or more embodiments, the viscosity of the alginate solution will be in the range of about 1 to about 20 cP, preferably about 1 to about 4 cP, at room temperature (about 20 to 25° C.). More specifically, the ratio of the viscosity of the hydrogel precursor solution to the viscosity of the alginate solution should be greater than 1 at room temperature. In one or more embodiments, the ratio of the viscosity of the hydrogel precursor solution to the viscosity of the alginate solution is about 1:1 to about 1000:1. In one or more embodiments, the ratio of the viscosities of the hydrogel precursors is about 20:1. In one or more embodiments, the viscosity of the hydrogel precursor solution is about 1 to about 500 cP, with about 40 to about 100 cP being particularly preferred at room temperature. The pH of the alginate bath should be in the range of about 6.2 to about 7.8, preferably about 6.6 to about 7.4.

[0028] The alginate shell forms from the inside out and thickens around the droplets as cations dissolve from the precursor solution droplets -- in other words, the presence of cations in the droplets causes the alginate in the bath to aggregate on the surface and cross-link around the droplets.

[0029] Gelation of the hydrogel precursor compounds in the liquid core is then initiated, such as by crosslinking and / or polymerization, resulting in core / shell crosslinked microparticles. In one or more embodiments, the core / shell microparticles are combined with a hydrogel matrix crosslinker, preferably in solution. The crosslinker elutes through the alginate shell into the core / shell microparticles, resulting in gelation (crosslinking) of the hydrogel precursor compounds to form a three-dimensional hydrogel matrix. The crosslinker corresponds to the hydrogel precursor compounds, but can be varied to control the rate and level of crosslinking achieved in the resulting crosslinked matrix. In general, the amount of crosslinker used to form the microparticles ranges from about 0.5 mM to about 30 mM, preferably from about 1 mM to about 20 mM, more preferably from about 2 mM to about 15 mM, even more preferably from about 2.5 mM to about 10 mM, and even more preferably from about 2.5 mM to about 5 mM, depending on the crosslinker and polymer system selected.

[0030] Each core / shell crosslinked microparticle comprises an alginate shell and a gelling core comprising a crosslinked three-dimensional hydrogel matrix. Crosslinking can be chemically induced, thermally induced, or photoinitiated, depending on the particular precursor solution being prepared. For example, a hydrogel crosslinker can be included in the alginate bath and diffuse through the alginate shell to crosslink the hydrogel microparticles in the core. Alternatively, the core / shell microparticles can be subjected to a UV radiation source to initiate crosslinking at the hydrogel microparticle core. UV exposure times range from about 1 minute to about 10 minutes, preferably from about 2 minutes to about 8 minutes, and even more preferably from about 2.5 minutes to about 5 minutes. The wavelength of the UV exposure will vary depending on the photoinitiator and / or polymer system selected, but is generally in the range of about 100 nm to about 400 nm, preferably from about 315 nm to about 400 nm, and even more preferably about 365 nm.

[0031] Suitable crosslinkers include photo- or thermally initiated crosslinkers, chemical crosslinkers such as acrylates, methacrylates, acrylamides, vinylsulfones, dithiols, etc., which are included as part of the alginate bath. Self-crosslinking hydrogel precursors may also be used. In these embodiments, a photoinitiator such as IRGACURE® 2959 (2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone) or lithium phenyl-2,4,6-trimethylbenzoyl-phosphinate (LAP) may be included in the hydrogel precursor solution as a catalyst. A photoinitiator may also be included in the alginate bath. For chemical crosslinking systems, the crosslinker is typically provided in the alginate bath. For UV-initiated crosslinking systems, the crosslinker may be included in the alginate bath or in the hydrogel precursor solution with the main polymer (backbone) species.

[0032] It will be appreciated that the precursor compounds are chemically altered in the final product via crosslinking reactions resulting in a fully crosslinked hydrogel matrix characterized as a porous elastic solid with defined particle morphology. For example, in one or more embodiments, the hydrogel matrix essentially consists (or consists of) a crosslinked network of PEG and HA polymers including thioether and ester crosslinks (e.g., in the case of thiolated HA). However, it will be appreciated that the matrix may include traces of unreacted precursor compounds, functional groups, etc. remaining in the network. Other examples of hydrogel matrices and crosslinks that may be present are described in the Examples. The list is illustrative and not exhaustive. Examples of scaffold molecules that can be used include chitosan, agarose, chondroitin sulfate, or combinations thereof. Bonds formed between the scaffolds include chemical bonds with thioether+ester, thioether+ester+methyl on the beta carbon, thioethersulfone, or thioethersuccinimide. However, other chemical bonds may be used. Photo (free radical) bonds may include ester+ether, or amide+ether, etc. It will be appreciated that the available combinations are increasingly complex and the possible combinations are virtually limitless.

[0033] Once the core is crosslinked, the alginate shell is then removed (e.g., using a chelating agent and / or mechanical agitation such as sonication) to obtain free-standing hydrogel microparticles or microbeads having the characteristics described elsewhere herein. In other words, the alginate shell is not part of the final product and is always removed prior to use of the microparticles. The resulting hydrogel microparticles can be recovered from the solution using a mesh screen or other device and, if desired, can be rinsed or suspended in a medium.

[0034] Other manufacturing methods include double emulsion, spraying, laser printing, 3D printing / additive manufacturing, and extrusion. Regardless of the manufacturing method, the resulting hydrogel matrix is ​​characterized as a semi-rigid network (i.e., a porous elastic solid) that is permeable to liquids and gases but does not exhibit flowability and retains its integrity at steady state. Hydrogel microparticles are matrix-type capsules that retain cross-linked filler material somewhat uniformly throughout the bead body, rather than having a distinct shell as in core-shell capsules. As mentioned above, each hydrogel microparticle is also a free-standing body with an exterior and a defined / discrete three-dimensional shape and geometry (as opposed to random particles or aggregates). In other words, the microparticles of the present invention are not threads, fibers, or sheets, nor are entangled threads, fibers, or sheets, nor are aggregates, clumps, specks, flakes, nor are branched chain structures or polymer chains or branched fragments. In one or more embodiments, the resulting microparticles have a controlled size and are preferably substantially monodisperse, with the coefficient of variation (i.e., the ratio of the standard deviation of the particles to the average particle diameter) between a given batch of synthesized microparticles being 20% ​​or less.

[0035] In one or more embodiments, the resulting microparticle bodies are substantially spherical (it is understood that the spherical bodies need not necessarily be perfectly circular, but may be elliptical, oval, egg-shaped, teardrop-shaped, etc.). That is, the microparticle bodies are preferably substantially round with a substantially smooth outer surface, without corners, preferably without sharp angles, as illustrated in the drawing images. In one or more embodiments, the microparticles have a sphericity or "roundness index" of at least 0.25, preferably at least 0.35, more preferably at least 0.49, even more preferably at least 0.7, and even more preferably from about 0.75 to about 1. The sphericity or roundness index is the ratio of the surface area of ​​a given particle to the surface area of ​​a perfect sphere having the same volume as the given particle. The sphericity or roundness index can be calculated by:

number

[0036] Advantageously, particle size is highly customizable depending on the capabilities of the droplet generator selected. In one or more embodiments, the resulting hydrogel microspheres or microparticles have an average particle size (i.e., average maximum cross-sectional surface-to-surface dimension) of greater than 30 μm, and in some cases, greater than 300 μm. For ease of reference, this cross-sectional dimension is referred to herein simply as the "size" of the microparticle. In one or more embodiments, the resulting hydrogel microspheres or microparticles have an average particle size of less than about 5 mm. Preferably, the resulting hydrogel microspheres or microparticles have an average particle size of less than about 2 mm, more preferably about 30 μm to about 2 mm, even more preferably about 50 μm to about 1.5 mm, more preferably about 150 μm to about 1.5 mm, and even more preferably about 300 μm to about 1.4 mm. In some cases, smaller microparticles can also be formed with sizes ranging from about 30 μm to about 750 μm or 500 μm. As stated above, regardless of size, substantially rounded particles have an aspect ratio of at least 0.5, preferably at least 0.7, and more preferably about 1.

[0037] In certain applications, it may be beneficial to produce a variety of sizes for a single application. In other cases, it is beneficial to the product for the particles in the suspension to have uniform particle size. In any event, the hydrogel microparticles of the present invention are not nano-sized and are not considered to be nanoparticles or any other type of nanocrystalline form.

[0038] The durability of the microparticles can be adjusted by varying various parameters of the microparticles, including formulation and / or processing parameters, such as the mass fraction or molecular weight of the polymer precursor, the molecular weight of the crosslinker, the ratio of crosslinker to polymer precursor, crosslinker hydrolysis, crosslinking kinetics, crosslinking time, e.g., UV exposure time, and combinations thereof. Additional hydrogels are described in co-pending PCT / US2020 / 036361, filed June 5, 2020, which is incorporated by reference in its entirety.

[0039] The microparticles are not drug delivery systems or vehicles for delivering small molecule compounds, cell tissues, or other "therapeutic agents" as defined herein, and in most embodiments may be "empty", i.e., substantially free of such drugs, biologics, cells, tissues, or other therapeutic payloads encapsulated therein or attached thereto. As used herein, "therapeutic" refers to compounds or materials that have activity / biological activity for treating or preventing diseases or conditions that are not related to or directly related to the care and restoration of the soft tissue filler placement site itself (to fill voids, plump skin, smooth wrinkles, etc.). Thus, the active compounds contemplated are only those intended to improve the outcome or restoration of the placement or implantation of the filler. The microparticles are also substantially free of metals, plastics, or ceramics. The term "substantially free" as used herein means that no ingredients are intentionally added to the composition, although there may be incidental impurities or residual / trace amounts remaining from the manufacturing process. In such embodiments, the hydrogel precursor solution composition contains less than about 0.05 wt. %, preferably less than about 0.01 wt. %, and more preferably about 0 wt. %, of such components, based on the total weight of the solution being 100 wt. %.

[0040] Notwithstanding the above, it is within the contemplated scope of the present invention that non-"therapeutic" payloads may be co-delivered with the microparticles, such as dyes or other detectable labels that may be used to visualize the microparticles. In one or more embodiments, contemplated payloads include local analgesics or anesthetics to reduce pain or infection at the injection site, such as lidocaine, antibiotics, anti-inflammatory agents, Botox, or other active agents that directly contribute to the successful placement, recovery, and outcome of the filler procedure of the soft tissue filler, such as by reducing pain, bruising, or inflammation at the imputation site. Such analgesics or anesthetics are not intended to "treat" the patient beyond temporary pain relief, bruising, or inflammation, and therefore are not included within the scope of "therapeutic agents." Local analgesics, antibiotics, or anesthetics may be injected into the microparticle hydrogel matrix and / or may simply be mixed with the microparticles in suspension, such as in a delivery vehicle, for administration of the composition.

[0041] Thus, the compositions disclosed herein are placed in, on, or under the dermis, mid-dermis, subcutaneous, subdermal, fascial, or periosteal regions of an individual by implantation (e.g., injection) as soft tissue fillers for cosmetic or aesthetic treatments such as plumping thin lips, enhancing shallow contours, softening facial lines, removing wrinkles, plumping hands, improving the appearance of scars, and for reconstructive surgery such as filling voids due to tissue loss or removal due to surgery, trauma, or the like. The route of administration of the hydrogel composition to an individual patient is generally determined based on the cosmetic and / or clinical effect desired by the individual and / or physician, and the body part or area to be treated. The compositions disclosed herein may be administered by any means known to those skilled in the art, including, but not limited to, needle syringes, pistols (e.g., hydraulic compression pistols), catheters, topical, or direct surgical implantation or placement. The administration of the microparticles may be once or repeated, for example, at regular intervals. Finally, the timing of use is subject to quality control standards. For example, the administration of the microparticles disclosed herein may be once or several times at intervals of several weeks. As used herein, the term "dermal region" refers to a region of skin that consists of the dermis, including the epidermal-dermal junction and the superficial dermis (papillary region) and the deep dermis (reticular region). Thus, the microparticles disclosed herein can be administered to an individual's dermal region, for example, by injecting into the epidermal-dermal junction, papillary region, reticular region, or any combination thereof.

[0042] The composition generally comprises a plurality of three-dimensional hydrogel microparticles suspended in a pharma- ceutically acceptable delivery vehicle (generally at a physiological pH in the range of 7-7.4 or slightly more alkaline, e.g., up to pH 8 or 9). The vehicle is preferably selected to be suitable for localized delivery (direct injection) at the implantation site, such as through a small gauge needle. In one or more embodiments, the hydrogel microparticles may be lyophilized and stored as a dry powder, and then reconstituted with a suitable aqueous vehicle. In one or more embodiments, the hydrogel microparticles may be frozen for storage and do not exhibit degradation of matrix quality upon thawing. Advantageously, due to the complete crosslinking nature of the microparticles, the soft tissue filler compositions described herein are heterogeneous mixtures or suspensions (not solutions) in which the microparticles are suspended in the delivery vehicle, preferably uniformly suspended, but remain and remain in suspension as having distinct properties per se. Thus, the microparticles may be separated from the delivery vehicle (or other vehicle used for storage) by filtration, if desired. Thus, the viscosity of the composition can be adjusted by adjusting the delivery vehicle selected. In the case of an aqueous delivery vehicle, including even sterile water, the composition can be very thin and low viscosity flowable, or the microparticles can be suspended in a carrier vehicle with a higher viscosity, such as a liquid polymer solution, if desired. In either case, the fully crosslinked microparticles remain a separate component of the heterogeneous composition and can be filtered or separated therefrom if desired.

[0043] In one or more embodiments, the delivery vehicle can be prepared as a hyperosmolar solvent system that reduces or minimizes swelling of the microparticles (thus reducing their size) while in suspension. However, upon injection and exposure to body fluids (and changes in salinity in the in vivo environment), the microparticles swell and expand to the desired size to fill defect voids (e.g., wrinkles, etc.). In this way, the microparticles remain small until placed in the body, facilitating injection with a small needle, while allowing the particles to swell in the body and fill or expand at the implantation site. Thus, the microparticles can be injected through any needle with a preferred size of about 27-24 gauge, or larger gauge needles up to about 14 gauge, depending on the particle size and the target site of implantation. In some embodiments, the microparticles may be sheared or fragmented into smaller particles as they pass through the needle.

[0044] In one or more embodiments, the swelling and shrinkage of the microparticles (after initial formation) can be modulated by co-suspending the fully crosslinked microparticles in a carrier vehicle with a solute capable of inducing shrinkage of the microparticles, as illustrated in the Examples. Increasing the concentration of this solute in the suspension will cause the microparticles to shrink. However, upon injection and exposure to body fluids (and concentration changes in the in vivo environment), the microparticles will swell and expand to a desired size to fill defect voids (e.g., wrinkles, etc.). In this way, the microparticle formulation remains small until it enters the body, facilitating injection with a small needle, while being able to swell and fill spaces in the body.

[0045] In one or more embodiments, a method of dermal, cosmetic, or reconstructive filling is contemplated herein. The method generally involves placing a plurality of hydrogel microparticles at or near a subject's implantation site, such as by injection or implantation. These novel soft tissue fillers are useful for treating skin conditions, generally facial and extremity volume loss, as well as for filling wrinkles. The implanted hydrogel microparticles provide cushioning volume and filling to the implantation site. As demonstrated in the examples, the microparticles also induce a favorable physiological response in the subject at the implantation site. For example, the microparticles do not induce an undesirable inflammatory response at the implantation site. In one or more embodiments, the methods contemplated herein include reducing wrinkles, adding volume, and aesthetically correcting deformities associated with surgery or injury from the dermis to the periosteum layer, such as after severe burns, tumors, or tissue removal (e.g., lipoma removal). The microparticles help restore or maintain structure and cushioning within the skin. Furthermore, due to their elasticity, they exhibit an elastic response that mimics native tissue.

[0046] The method can be applied to a variety of human applications including, but not limited to, wrinkles on the face, neck, and hands, as well as the arms, legs, abdomen, hands, and feet, as well as volume filling of such areas. Preferably, the microparticles or compositions comprising the microparticles are introduced into the dermal region as well as the subcutaneous tissue, or even the periosteum.

[0047] For therapeutics, the microparticles are suspended or dispersed in a suitable delivery vehicle for administration to a subject. Exemplary delivery vehicles include compatible biological fluids, and biocompatible liquid suspensions, viscous solutions, putties, pastes, or gels, such as non-crosslinked or partially crosslinked low concentration HA liquid solutions, in which the microparticles are dispersed. Saline or other buffer solutions can also be used as vehicles for delivery. An injection composition may contain a single formulation of microparticles in a narrow size range (substantially monodisperse), such as, for example, 400-600 μm in diameter. Conversely, a composition may be a mixture of formulations with different microparticle sizes (polydisperse). For example, it may be advantageous to mix different formulations of hydrogels to have a combination of microparticles that degrade at different times or have different stiffness properties. Thus, contemplated herein is a composition of different microparticles comprising a first microparticle population having a first characteristic (e.g., size range, stiffness, and / or degradation profile, etc.) and a second microparticle population having a second characteristic (e.g., size range, stiffness, and / or degradation profile, etc.), the second characteristic being different from the first characteristic. The mixed composition may contain 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more different microparticle formulations. Similarly, the viscoelastic microparticles of the present invention can be mixed (as a carrier vehicle) with uncrosslinked or only partially crosslinked viscous HA, or other viscous dermal fillers to obtain a suitable formulation. The product may, for example, consist of a 1:10 ratio of microparticles suspended in a viscous dermal filler, such as partially crosslinked HA.

[0048] More generally, the method comprises (or consists of) locally administering to a patient a cosmetically or aesthetically effective amount of the resulting microparticle composition. Administration typically involves direct injection of the microparticle composition at or near the target site. Advantageously, durable microparticles are generally confined to a localized area for a cosmetically or aesthetically effective period of time. As used herein, the term "cosmetically or aesthetically effective" refers to an amount and / or period of time that maintains the cosmetic or aesthetic response of tissue desired by a researcher, clinician, or patient.

[0049] Treatment can be repeated with additional injections or infusions if necessary. Those skilled in the art will appreciate that treatment protocols are variable depending on the particular aesthetic target and the preferences of the medical practitioner or researcher. Examples of typical injection procedures include continuous injections, linear threading, fan-shaped injections, and cross-hatching for larger surface areas. The compositions described herein are particularly contemplated for use as dermal fillers.

[0050] Advantageously, the hydrogel microparticles are durable, meaning that they do not disintegrate or degrade under storage conditions in PBS at 37° C. for at least six months. In other words, the durable microparticles have an "in vitro storage stability" of greater than six months. In one or more embodiments, the durable hydrogel particles are storage stable in PBS at room temperature (27° C.) for more than one year, with current data illustrating microparticles with a shelf life of greater than four years. Preferably, such durable hydrogel microparticles, when implanted, do not disintegrate under normal physiological (meaning normal in vivo clearance of foreign material via phagocytosis, degradation, adsorption, etc.) conditions for at least three months, more preferably at least six months.

[0051] A particular advantage of the compositions and microparticles of the present invention is that they have improved "stickiness" when implanted compared to other types of microparticles; that is, they tend to adhere or stick to tissue at the implantation site in vivo, as shown in the photographs of the examples below. This further enhances the efficacy of the treatment by maintaining localized filling at the implantation site. Furthermore, the microparticles do not exhibit any inflammatory response at the implantation site, and / or induction of any foreign body response, including lymphocyte or collagen ring formation.

[0052] Another particular advantage of the compositions and microparticles of the present invention is their ability to dissolve on demand. This is important in situations where the end user may misapply the product to a particular area, where the cosmetic effect is not as desired, or where unexpected effects such as the Tyndall effect are observed. In this case, the hydrogel microparticles need to dissolve within a few hours to a few days. Many different approaches can be taken to achieve on-demand dissolution, as described in the examples below and summarized in Tables 5 and 6.

[0053] Further advantages of various embodiments of the present invention will be apparent to those skilled in the art upon reviewing the disclosure of this specification and the following examples. It will be understood that the various embodiments described herein are not necessarily mutually exclusive, unless otherwise indicated herein. For example, features described or depicted in one embodiment may, but are not necessarily, included in other embodiments. Thus, the present invention encompasses various combinations and / or integrations of the specific embodiments described herein.

[0054] As used herein, the term "and / or," when used in a list of two or more items, means that any one of the listed items may be taken by itself, or any combination of two or more of the listed items may be taken. For example, if a composition is described as containing or not containing components A, B, and / or C, the composition may contain or not contain A alone; B alone; C alone; a combination of A and B; a combination of A and C; a combination of B and C; or a combination of A, B, and C.

[0055] Numerical ranges are also used herein to quantify certain parameters related to various embodiments of the present invention. When numerical ranges are provided, it should be understood that such ranges are interpreted as providing literal support for the claim limitations that recite only the lower limit of the range as well as the claim limitations that recite only the upper limit of the range. For example, a disclosed numerical range of about 10 to about 100 provides literal support for claims that are recited as "greater than about 10" (without upper limit) and claims that are recited as "less than about 100" (without lower limit). EXAMPLES

[0056] Working Example The following examples illustrate methods according to the present invention, however, it should be understood that these examples are given for illustrative purposes and that nothing contained therein should be construed as limiting the overall scope of the invention.

[0057] Characterization of the final hydrogel microparticles Crosslinked microparticles can be constructed using many different manufacturing methods, including but not limited to core-shell spheronization, emulsion, alginate extrusion, pattern casting, and printing. Microparticles are typically small enough to be injected through a needle or infused through a catheter. We have produced microparticles ranging in size from less than 150 μm to more than 1,500 μm, and therefore can pass through an 18-30 G needle, making them easy to inject into the skin. However, microparticles can be made with diameters of less than 50 μm, so even smaller needles can be used. The size and shape of the microparticles can be varied to suit the therapeutic goal. Figure 1 shows examples of spherical (Figure 1A), teardrop-shaped (Figure 1B), oval (Figure 1C), and organic large tubular (Figure 1D) microparticles. They can also be tubular, rectangular, or other shapes. Additionally, a mixture of shapes can be produced and used in the same product, as shown in Figure 1E. The particles can withstand physical forces such as shear. However, when excessive force is applied, the particles break into small pieces but maintain a defined physical shape. This differs from pasty lubricant gels, which do not maintain physical boundaries and a defined shape. Figure 2 shows MeHA microparticles before (Figure 2A) and after (Figure 2B) exposure to shear. The shear force causes the microparticles to break apart, but they still maintain a solid-like shape. AHA microparticles impregnated with a fluorescent probe are shown before (Figure 2C) and after (Figure 2D) exposure to shear force.

[0058] Similarly, microparticles can be produced in a wide range of sizes, averaging 100-2000 microns, as shown in Figure 3. Large microparticles are shown in Figure 3A, medium sizes in Figure 3B, small microparticles in Figure 3C, and a mixture of sizes in Figure 3D. In theory, a mixture of large and small sizes may provide a smoother product as a dermal filler.

[0059] By utilizing different precursor polymers and crosslinking schemes, crosslinked microparticles can be fabricated from a variety of materials. Figure 4 shows some examples of microparticles fabricated from thiolated hyaluronic acid (ThHA), polyvinyl alcohol acrylamide (PVA-AA), diacrylate polyethylene glycol polyethylene diacrylate (PEGDA), alginic acid, polyethylene vinyl sulfone, and acrylated hyaluronic acid (AHA).

[0060] Hydrogel microparticles can be advantageously constructed from hyaluronic acid (HA) and various slow-gelling polymer precursors such as polyethylene glycol diacrylate (PEGDA), polyethylene glycol maleimide (PEGMAL), multi-arm PEG, hyaluronan, fibrin, chitosan, collagen, heparin, polylactic acid (PLA), poly(L-lactic acid) (PLLA), polylactic-co-glycolic acid (PLGA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), methacrylic acid (MAA), 2-hydroxyethyl methacrylate (HEMA), polyacrylamide (PAM) extracellular matrices, and their functionalized variants (e.g., acrylated, methacrylated, thiolated, etc.) or their multi-arm variants (e.g., 4-arm PEG, 8-arm PEG). However, any crosslinkable hydrogel precursor compound is suitable for use herein, with preferred compounds being biocompatible homopolymers or copolymers, particularly block copolymers, as well as other types of crosslinkable monomers and / or oligomers.

[0061] Further characterization of several chemical types of the final products is shown in Table 2. The precursor polymers and potential crosslinkers are shown along with the crosslinking mechanisms. The first row shows the diversity of viscoelastic solid microparticle characteristics including reactive groups, crosslinkers, crosslinking time, range of polymer masses, and range of particle diameters. A variety of crosslinking mechanisms are available including photoinitiation and chemical reaction (Table 2), therefore different crosslinking approaches require different times for cure, as shown in Table 2.

[0062] [Table 2]

[0063] The microparticles listed in Table 2 vary greatly in swelling properties. For example, AHA has a swelling ratio (Q value) of approximately 250, whereas ThHA is only 28. Hydrogel chemistry provides a high degree of control over swelling properties such that the microparticles can be maintained in an environment that inhibits swelling until after injection. This situation is advantageous as it allows the use of smaller needles and entry points into the skin while still providing a high degree of volume gain.

[0064] In addition to the various crosslinking approaches, further chemical modifications can be performed to alter the characteristics of the microparticles. For example, unreacted species within fully crosslinked particles can be further modified as shown in Figure 5. This can be done to change the interaction of the particles with the surrounding tissue, making them less or more reactive depending on the application. In this example, there is generally a low level of residual reactive groups in the hydrogel after crosslinking. These groups can be utilized for downstream functionalization, if desired. In this example, a monofunctional PEG-maleimide "molecular cap" is used to quench residual thiol groups. As can be seen in this example, treatment of hydrogel spheres with a molecular cap successfully blocked binding of maleimide-conjugated fluorescent dyes, whereas untreated spheres readily conjugated the dye.

[0065] The described approach offers a wide range of options for producing viscoelastic solid dermal fillers. The differences become clear when comparing the properties of the viscoelastic microparticles described here with those of currently commercially available paste-type dermal fillers. First, it is known in the cosmetic field that the higher the molecular weight of the filler, the longer it will last in vivo. Table 3 compares the molecular weight of the final crosslinked solid microparticles with that of currently commercially available paste-type fillers. The starting molecular weight of the precursor of the solid viscoelastic microparticles can be 0.2 MDa, as shown in the example in Table 3, but when fully crosslinked, the value increases to an indeterminable extent. Essentially, the entire bead acts as a single molecule. In contrast, currently commercially available paste-type dermal fillers may start with a high molecular weight precursor, but studies have shown that the actual final product has a lower molecular weight after processing.

[0066] The crosslink percentage in the product also differs significantly for viscoelastic solid microparticles compared to paste-like fillers. Once formed, viscoelastic solid microparticles have preferably 20% or more crosslinking, preferably 20%-30% crosslinking, while all other products have less than 20% (Table 3). The particle diameters are all in a similar range, but the viscoelastic solid microparticles have a defined, non-angular surface. The final concentration of HA in the product is nearly twice as high for the viscoelastic solid microparticles as for the paste-like products. The durability of the paste-like filler is directly related to the molecular weight of the precursor and the crosslinking % of the gel. Table 3 shows that the molecular weight of the final product is not determined, as crosslinking results in single microparticles with an unmeasurable molecular weight. It is important that the stiffness is not high, as this may result in an unnatural appearance. Therefore, a lower stiffness (G') value compared to currently available products is advantageous. It should also be noted that the stiffness measurements for microparticles are different from bulk gels, so the values ​​cannot be directly compared.

[0067] [Table 3]

[0068] The same general differences apply when comparing viscoelastic solid hydrogel microparticles with currently available non-HA paste-like products (Table 4). Although independent measurements were not reported, the initial and final molecular weights of the non-viscoelastic pastes are likely unchanged. However, the viscoelastic solid microparticles show a dramatic increase in molecular weight as noted for the HA-based microparticles. This difference again results in a harder and presumably more durable product.

[0069] [Table 4]

[0070] In vitro degradation rate In contrast to these non-crosslinked forms of HA, one formulation of our fully crosslinked HA microparticles has an in vitro half-life of approximately 50 days, whereas microparticles made from a polyethylene glycol-based formulation have an in vitro duration of indefinite duration. In this experiment, the microparticles were maintained at 37°C and 10% humidity for 50 days.

[0071] In the body, the degradation of HA microparticles is dependent on endogenous enzymes such as hyaluronidase. Preliminary in vitro studies will demonstrate enzymatic degradation of fully crosslinked microparticles. To be able to monitor microparticle degradation in vivo, we developed fluorescent microparticles. SAMSA fluorescein was added to the precursor AHA solution shown in Figure 6A. Figure 6B shows the fluorescent labeling of PEGDA microparticles.

[0072] Solute-controlled microparticle size Changes in microparticle diameter can be obtained through a solute-controlled approach that utilizes heuristics of a process known as aqueous two-phase extraction in the context of hydrogels (Gehrke et al., 1998). This approach has been utilized in the past to load proteins onto hydrogels. In this iteration, it is used to reduce the size of the microparticles to make them easier to inject with small needles. Hydrogel microparticles are typically stored in normal phosphate buffered saline. However, when a polymer such as PEG is co-dissolved in the storage solution, a second aqueous phase forms within the hydrogel network. This ultimately disrupts the interactions between water and the hydrogel polymer, reducing the swelling force and thus reducing the size of the microparticles. In the experiments in Figures 7-11, PEG (molecular weight 20 kDa) was dissolved in the storage solution at 5, 10, 20, and 30% by mass. As shown in Figure 7, the reduction in size was directly related to the concentration of PEG in the solution. In this figure, HA-based microbeads show minimal reduction in diameter for increasing solute concentration, whereas PVA-based hydrogels show a dramatic reduction in diameter for the same solute concentration.

[0073] Figure 8 shows a comparison of different hydrogel formulations and their size reduction capabilities. Figure 8A compares HA and PVA hydrogel microparticles. Both showed a decrease in diameter with increasing solute percentage up to 30%. In Figure 8B, lower solute concentrations also led to a decrease in diameter. With increasing solute concentrations, the microparticles could not be imaged. The same trend was observed when measuring the volume of the microparticles (Figures 9A and B). The change in volume with solute concentration was visually tracked in Figure 10.

[0074] The reduction in diameter is reversible by replacing the solute-containing storage solution with normal phosphate buffered saline. Figure 11A shows the level of reduction in microparticle diameter with increasing solvent concentration (light grey). When the microparticles were returned to a solute-free solution, the microparticle diameter returned to its original size. Figure 11A shows the change in diameter of HA-based microparticles. Figure 11B shows the change in PVA microparticles. Figure 11C shows the change in diameter of PEG-based microparticles. No change in size of PEG microparticles could be measured in high solute concentrations, but when returned to solute-free conditions (dark grey), the microparticles were visible.

[0075] Biocompatibility of Microparticles Microparticles were injected subcutaneously into rats to examine biocompatibility. Microparticles were injected either in a bolus amount (Figure 12A) or as individual microparticles (Figure 12B). Images were acquired 2 weeks after injection of the microparticles and showed no signs of gross inflammation (redness or swelling). The biocompatibility of microparticles is shown in Figure 13 when hydrogel particles were made from PEGDA, ThHA, or AHA using the same technique. Microparticles were injected intraperitoneally into rats and after 2–10 weeks, intact hydrogel microspheres were still visible in the area. The area of ​​fibrosis (collagen ring) and inflammatory response (macrophages and lymphocytes) was measured at four different locations around each microsphere by two blinded technicians. Only limited fibrosis was seen around some microparticles (Figure 13; ThHA). The AHA microparticles had the least amount of fibrosis. If fibrosis was seen around the AHA microparticles, it was much smaller than for particles made from the other components. Additionally, the width of the field of inflammatory cells around the microparticles was measured: Fewer AHA samples showed signs of inflammatory cells around the microparticles.

[0076] Not only is there little to no reaction in the surrounding tissue, but when the loose viscoelastic microparticles are removed from the site, there are no inflammatory cells or fibrosis coating the biomaterial, as shown in Figure 14. In the image on the left, a few inflammatory cells are surrounding or attached to the microparticle, but no fibrotic ring is present.

[0077] When solid microparticles dissolve or otherwise degrade, degradation begins at the surface yet does not elicit a foreign body response (Figure 15). Figure 15A shows freshly deposited AHA microparticles, yet there is no foreign body response in the surrounding omentum. Ten weeks after implantation, the microparticles have degraded from the surface, yet there is still no foreign body response (Figure 15B). This is in contrast to non-biocompatible materials, which can elicit a strong foreign body response that destroys the microparticles, as shown in the rat omentum example in Figure 15C.

[0078] Planned Disassembly Occasionally, microparticles must be removed due to user error or recipient physiological issues such as allergies. Cross-linking chemistry can be designed such that the beads fall apart in a few hours to days. Figure 16 shows the degradation of microparticles following exposure to enzymes such as hyaluronidase for HA-based microparticles. An alternative method of deliberate degradation utilizes chemical dissolution. In Figure 17, microparticles were exposed to DTT and completely dissolved in 15 minutes. Figures 18A-B list the resulting by-products, illustrating some of the chemistry behind deliberate degradation.

[0079] When chemically crosslinked microparticles are involved, lysis reagents can be injected into the area of ​​interest. Table 5 outlines the possible crosslinking reactions and the lysis reagents used in each situation. Reagents such as glutathione can be injected into the site of hydrogel microparticles containing disulfide bonds for on-demand lysis.

[0080] [Table 5]

[0081] In addition to chemical dissolution of viscoelastic hydrogel microparticles, physical modalities can also be used to break crosslinks and dissolve the microparticles. Table 6 shows the chemical properties of hydrogel microparticles and some examples of possible physical and chemical dissolution methods. For example, methacrylate-crosslinked hyaluronic acid microparticles can be dissolved using enzymes such as hyaluronidase or by excitation light emitted from a two-photon laser. In another example, alginate microparticles can be dissolved by applying high-intensity ultrasound to the skin surface. Visible and UV light can also be used to dissolve thiol-crosslinked polyvinyl alcohol-based microparticles. Red light can be used to dissolve azo-crosslinked poly(acrylic) acid-based microparticles. In these methods, a handheld device can be applied to the skin to dissolve the viscoelastic solid microparticles. In contrast, there is no way to dissolve some current dermal fillers. This is the case for ARTEFILL®, which is made from PMMA (Table 4). If the product must be removed, the only option is invasive surgery.

[0082] [Table 6]

[0083] Specific handheld instruments can be used or developed that generate ultrasound or UV light, or a two-photon laser, for the purpose of dissolving the microparticles when applied to the surface of the skin. Currently, a variety of existing light wands are available.

[0084] Shelf life of microbeads Informally, we have stored PEG-based hydrogel microbeads in PBS at room temperature for over four years without any visible deterioration in physical properties. Figure 19 shows two example images of thiolated hyaluronic acid imaged after storage at room temperature in water for over four years. More formally, we have frozen and stored the microspheres and measured their structural integrity after thawing.

[0085] The final cross-linked product can be frozen using a slow freezing protocol without adversely affecting the chemical properties of the microparticles' physical properties, and it was found that the microparticles maintained their structure and surface shape when thawed at 37° C. for approximately 2 minutes. Figure 20 shows photographs of the microparticles before and after freezing and thawing at −80° C., showing no change in size, shape, or microscopic structure.

[0086] Sterilization of Microparticles The production of microparticles using the CSS method is a completely closed, sterile system. However, production by other means, such as emulsion, is not easily subject to sterile conditions per se. In such cases, the final product may require sterilization. Table 7 shows the results of a sterilization experiment in which the final form of microparticles was sterilized by autoclaving.

[0087] [Table 7]

Claims

1. 1. A method for aesthetic or cosmetic soft tissue filling in a human subject, the method comprising placing at an implantation site in a subject in need thereof a suspension comprising a plurality of porous, viscoelastic, solid hydrogel microparticles dispersed in a carrier vehicle, each microparticle being free-standing having an exterior surface and a defined / discrete three-dimensional shape and geometry, said microparticles being substantially free of any cells, tissues, or therapeutic compounds.

2. 2. The method of claim 1, wherein the suspension is placed in the superficial dermis, mid dermis, subcutaneous, fascial, muscular, or periosteal layer of the subject.

3. 3. The method of claim 1 or 2, wherein the implantation site is an area of ​​a subject needing or desiring additional tissue volume and fullness to reconstruct a void due to surgery or trauma, to improve or enhance the subject's appearance.

4. The method of any one of claims 1 to 3, wherein the suspension is placed at the implantation site by injection.

5. 5. The method of claim 4, wherein the suspension is injected through an injection device having an orifice smaller than the particle size of the microparticles, and the microparticles break up upon injection.

6. The method of any one of claims 1 to 5, wherein the hydrogel microparticles are characterized as free-standing bodies having a three-dimensional matrix of covalently or ionically crosslinked polymeric compounds.

7. 7. The method of claim 6, wherein the polymeric compound is selected from the group consisting of hyaluronic acid, polyethylene glycol, hyaluronan, fibrin, chitosan, collagen, heparin, polylactic acid (PLA), poly(L-lactic acid) (PLLA), polylactic-co-glycolic acid (PLGA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), methacrylic acid (MAA), 2-hydroxyethyl methacrylate (HEMA), polyacrylamide (PAM) extracellular matrix, and functionalized variants thereof.

8. The method according to any one of claims 1 to 7, wherein the defined / discrete three-dimensional shapes and geometries are rounded shapes and geometries with a sphericity Ψ greater than 0.

25.

9. The method according to any one of claims 1 to 8, wherein the hydrogel microparticles have a particle size greater than 30 μm and smaller than 2 mm.

10. The method of any one of claims 1 to 9, wherein the hydrogel microparticles induce a beneficial physiological response at the implantation site in a subject.

11. The method of any one of claims 1 to 10, wherein the hydrogel microparticles enhance the quantity or quality of tissue volume at the implantation site.

12. The method of any one of claims 1 to 11, wherein the hydrogel microparticles provide an elastic response to provide a natural appearance at the implantation site.

13. 13. The method of any one of claims 1 to 12, wherein the hydrogel microparticles have a first particle size in the suspension, the microparticles swell after introduction to an implantation site, and the microparticles have a second particle size at the implantation site that is larger than the first particle size.

14. 14. The method of any one of claims 1 to 13, wherein the suspension further comprises a solute in suspension with the microparticles, the solute causing the microparticles to shrink in the suspension such that the microparticles have a first particle size in the suspension, and the microparticles have a second particle size at the implantation site that is greater than the first particle size due to a decrease in concentration of the solute after the placement at the implantation site.

15. 15. The method of any one of claims 1 to 14, wherein the plurality of porous viscoelastic solid hydrogel microparticles comprises at least two distinct microparticle populations, a first microparticle population comprising a plurality of microparticles having a first characteristic and a second microparticle population comprising a plurality of microparticles having a second characteristic, said first characteristic being different from said second characteristic.

16. The method of any one of claims 1 to 15, wherein the delivery vehicle is a buffered saline solution, a viscous solution, a putty, a paste, or a gel, and optionally contains an anesthetic, an antibiotic, or an analgesic.

17. The method of any one of claims 1 to 16, wherein the hydrogel microparticles are injected directly into the implantation site.

18. The method of any one of claims 1 to 17, wherein the hydrogel microparticles are provided in a composition in a pre-loaded syringe for injection into the body.

19. 19. The method of any one of claims 1 to 18, wherein the hydrogel microparticles are confined to the implantation site for a cosmetically or aesthetically effective period of time.

20. The method according to any one of claims 1 to 19, wherein the hydrogel microparticles remain at the implantation site without degradation for at least six months under normal physiological conditions.

21. 21. The method according to any one of claims 1 to 20, wherein the human subject receives repeated doses of the hydrogel microparticles administered at intervals of every 6 months, preferably every 6 to 12 months, preferably every 1 to 5 years.

22. 22. The method of any one of claims 1 to 21, further comprising dissolving the microparticles at the implantation site by introducing a chemical or enzyme to the implantation site.

23. 23. The method of any one of claims 1 to 22, further comprising dissolving the injected microparticles at the implantation site by introducing a physical stimulus, such as sound waves or UV light, to the implantation site.

24. 1. A kit for cosmetic or aesthetic soft tissue filling comprising a plurality of porous elastic solid hydrogel microparticles, each microparticle having an exterior surface and a defined / discrete three-dimensional shape and geometry, and being free-standing, substantially free of any cells, tissues, or therapeutic compounds, and instructions for administration thereof.

25. 25. The kit of claim 24, wherein the plurality of porous elastic solid hydrogel microparticles are lyophilized, and the kit further comprises a carrier vehicle in a separate container for reconstituting the hydrogel microparticles or instructions for reconstituting the hydrogel microparticles prior to administration.

26. 26. The kit of claim 25, further comprising a syringe and instructions for loading the syringe with the reconstituted hydrogel microparticles.

27. 25. The kit of claim 24, wherein the plurality of porous, viscoelastic, solid hydrogel microparticles are packaged as a suspension, the suspension being preloaded into a syringe for administration and instructions therefor.

28. 25. The kit of claim 24, wherein the plurality of porous, viscoelastic, solid-state hydrogel microparticles are packaged as a suspension, the kit comprising an empty syringe and the hydrogel microparticles in a separate container configured to allow withdrawal of the suspension from the container for loading into the syringe prior to the administration, and instructions therefor.

29. 25. The kit of claim 24, further comprising a separate container comprising a dissolving chemical or enzyme for optionally removing the implanted viscoelastic solid hydrogel microparticles.

30. 25. The kit of claim 24, further comprising a handheld device for dissolving the implanted viscoelastic solid hydrogel microparticles on demand by application of light, sound, or ultrasound energy.

31. 30. The kit of claim 28, wherein the plurality of porous viscoelastic solid state hydrogel microparticles are packaged as a storage suspension comprising a solute that causes the microparticles to shrink in the suspension such that a first particle size of the microparticles in the storage suspension is smaller than a particle size of the microparticles after administration to a subject.

32. 1. A composition for use in aesthetic or cosmetic soft tissue filling in a human subject, characterized as a suspension comprising a plurality of porous, viscoelastic, solid hydrogel microparticles dispersed in a carrier vehicle, each microparticle being free-standing having an exterior surface and a defined / discrete three-dimensional shape and geometry, said microparticles being substantially free of any cells, tissues, or therapeutic compounds.

33. 1. Use of a composition for aesthetic or cosmetic soft tissue filling in a human subject, said composition being characterized as a suspension comprising a plurality of porous, viscoelastic, solid hydrogel microparticles dispersed in a carrier vehicle, each microparticle being free-standing having an exterior surface and a defined / discrete three-dimensional shape and geometry, said microparticles being substantially free of any cells, tissues, or therapeutic compounds.

Citation Information

Patent Citations

  • Cosmetic neurotoxin compositions and methods containing botulinum toxin components

    JP2008514353A

  • Thermomechanically controlled implant and method of use

    JP2010518980A

  • Compositions and kits of pseudoplastic microgel matrices

    JP2018511622A